Finance

Lists
Why is IONS down 2,35%?
Dive Deeper
IONS:NASDAQ
Ionis Pharmaceuticals Inc
26,58 USD
-2,35%
(-0,64) 1D
26,61 USD
+0,11% (+0,030)
After hours
Closed: 20-ноя., 16:00:02 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IONS...
Open
26,92 USD
High
28,07 USD
Low
26,53 USD
Mkt. cap
4,43 млд
Avg. vol.
4,13 млн
Volume
3,18 млн
52-wk high
86,74 USD
52-wk low
26,53 USD
EPS
-3,33 USD
Beta
0,43
Shares outstanding
166,54 млн
No. of employees
1 миң
Open
26,92 USD
High
28,07 USD
Low
26,53 USD
Mkt. cap
4,43 млд
Avg. vol.
4,13 млн
Volume
3,18 млн
52-wk high
86,74 USD
52-wk low
26,53 USD
EPS
-3,33 USD
Beta
0,43
Shares outstanding
166,54 млн
No. of employees
1 миң
News stories
From web sources and news partners
Profile
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015. Wikipedia
About Ionis Pharmaceuticals Inc
CEOBrett P. Monia Ph.D.
Employees1,48 миң
Founded1989
HeadquartersКарлсбад, Калифорния, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websiteionis.com
Analyst ratings
Based on 19 analysts giving stock ratings to IONS in the past 3 months
Strong buy
Buy
18
Hold
1
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for IONS in the last 3 months.
Highest
Current 26,58 USD
100,00 USD (+276,22%)
Average
71,56 USD (+169,22%)
Lowest
41,00 USD (+54,25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
65,00 USD
+144,5%
11/17/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
70,00 USD
+163,4%
11/16/2026
David Lebowitz
BMO Capital
Buy
Maintained
66,00 USD
+148,3%
11/10/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
41,00 USD
+54,3%
11/09/2026
Justin Kim
Oppenheimer
Buy
Reiterated
70,00 USD
+163,4%
11/10/2026
Yaron Werber
TD Cowen
Buy
Maintained
53,00 USD
+99,4%
11/10/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
75,00 USD
+182,2%
11/10/2026
Joon Lee
UBS
Buy
Maintained
81,00 USD
+204,7%
11/09/2026
Gary Nachman
Canaccord Genuity
Buy
Maintained
72,00 USD
+170,9%
11/10/2026
Luca Issi
RBC Capital
Buy
Maintained
60,00 USD
+125,7%
11/09/2026
Eric Joseph
Citi
Buy
Maintained
100,00 USD
+276,2%
11/09/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
80,00 USD
+201%
11/10/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
63,00 USD
+137%
11/09/2026
Eliana Merle
Barclays
Buy
Maintained
70,00 USD
+163,4%
11/11/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
87,00 USD
+227,3%
11/09/2026
Tiago Fauth
Raymond James
Buy
Maintained
79,00 USD
+197,2%
10/20/2026
Joseph Stringer
Needham
Buy
Maintained
86,00 USD
+223,6%
09/23/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/22/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
70,00 USD
+163,4%
09/22/2026
Unknown Analyst
BMO Capital
Hold
Initiated
60,00 USD
+125,7%
08/19/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
95,00 USD
+257,4%
08/14/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
68,00 USD
+155,8%
08/02/2026
Andy Chen
Wolfe Research
Hold
Downgraded
-
-
07/15/2026
Akash Tewari
Jefferies
Buy
Maintained
90,00 USD
+238,6%
07/15/2026
Unknown Analyst
Guggenheim
Buy
Maintained
106,00 USD
+298,8%
06/05/2026
Unknown Analyst
Citi
Buy
Initiated
115,00 USD
+332,7%
05/15/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
110,00 USD
+313,8%
04/20/2026
Unknown Analyst
Raymond James
Buy
Initiated
104,00 USD
+291,3%
04/10/2026
Last report
2026-ж., 9-ноя.
Fiscal period
Q3 2026
-0,40 USD / -0,93 USD
+56,81%beat
Revenue / Est. (USD)
242,72 млн / 184,38 млн
+31,64%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
203,33 млн
246,09 млн
267,95 млн
242,72 млн
Cost of goods sold
309,20 млн
213,16 млн
208,75 млн
207,50 млн
Cost of revenue
309,20 млн
213,16 млн
208,75 млн
207,50 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
108,59 млн
150,36 млн
160,60 млн
164,72 млн
Operating expense
108,59 млн
150,36 млн
161,50 млн
165,92 млн
Total operating expenses
417,79 млн
363,52 млн
370,24 млн
373,42 млн
Operating income
-214,46 млн
-117,42 млн
-102,29 млн
-130,70 млн
Other non operating income
57,00 миң
-456,00 миң
987,00 миң
277,00 миң
EBT including unusual items
-227,92 млн
-92,31 млн
-113,38 млн
-110,11 млн
EBT excluding unusual items
-212,36 млн
-114,89 млн
-103,20 млн
-119,64 млн
Income tax expense
1,48 млн
218,00 миң
1,26 млн
-141,00 миң
Effective tax rate
-0,65%
-0,24%
-1,11%
0,13%
Other operating expenses
-
-
900,00 миң
1,20 млн
Net income
-229,39 млн
-92,53 млн
-114,65 млн
-109,97 млн
Net profit margin
-112,82%
-37,60%
-42,79%
-45,31%
Earnings per share
-1,15
-0,30
-0,42
-0,40
Interest and investment income
24,73 млн
25,48 млн
20,23 млн
19,54 млн
Interest expense
-22,69 млн
-22,50 млн
-22,12 млн
-8,76 млн
Net interest expenses
2,04 млн
2,99 млн
-1,89 млн
10,79 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-210,56 млн
-113,46 млн
-98,16 млн
-126,37 млн
Gain or loss from assets sale
638,00 миң
40,00 миң
441,00 миң
815,00 миң
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору